The CDV laboratory, after its successful operation with Indonesia, where it exported 6,000,000 total doses of foot-and-mouth disease vaccines in 2022, opened new markets, this time in the Southern Cone region. The company specializing in the production of biologicals for the prevention of diseases that affect cattle and sheep herds, has been selected by Uruguay as a qualified supplier for the shipment of 1 million doses of foot-and-mouth disease vaccines, within the framework of a campaign that includes 16 million doses to be applied between the first and second campaign of 2023.
After having participated in an International Public Tender for foot-and-mouth disease convened by the Ministry of Livestock, Agriculture and Fisheries (MGAP) of Uruguay, together with eight laboratories, CDV has become a supplier of doses for the 2023 campaign.
Uruguay, like Argentina, are countries where clinical surveillance does not detect the presence of the disease and serological studies show the absence of viral circulation in their territories, a condition that recognizes them with the status “free of foot-and-mouth disease with vaccination” before the World Organization for Animal Health (OIE), an international organization in charge of recognizing the health status of a country or zone with respect to Foot-and-Mouth Disease. To maintain the status, tests are carried out every year to demonstrate the absence of the disease, with preventive vaccination campaigns being key to maintaining the sanitary status and controlling the disease.
The objective of Uruguay is to be able to continue exporting more than 80% of the meat it produces and to maintain its condition of being a country “free of Foot-and-Mouth Disease with vaccination”, which allows them access to different world markets such as Japan, South Korea South, China, the United States, Canada, the European Union, among others.
In this context, the Argentine firm CDV, which has a plant dedicated to the exclusive manufacture of vaccines against Foot-and-Mouth Disease, the most modern in the region and enabled by SENASA in 2017, with a production capacity of more than 40 million doses of vaccine. mono, bi, tri and tetravalent per year; deepens its fight for the preservation of animal health, not only locally but also in the South American region.
The company has an international presence in different markets around the world and has the capacity to manufacture products adapted to the requirements and needs of each country. In the coming years, it will continue its development and growth with the construction of a third vaccine manufacturing plant in the Pilar Industrial Park, with an area of 11,000 mt2 and which will be operational in the first quarter of 2025. Its capacity will amount to a total of 280 million mt2. doses, of which 190 million correspond to vaccines for bovines to prevent the main diseases that affect production (destined for the domestic market and for export) and the rest correspond to vaccines for salmonids.
